Keryx, CEO Dodge Investor Class Action Over Cancer Drug
A New York federal judge on Friday threw out a putative class action brought against Keryx Biopharmaceuticals Inc. and the company's CEO by investors who said they were misled about the...To view the full article, register now.
Already a subscriber? Click here to view full article